Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bit Digital Inc (BTBT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BTBT trades at $1.69, showing slight positive momentum with a 0.6% daily gain, but faces a bearish technical outlook with 15 sell signals versus 3 buys. The company reported a net loss of $80.32 million in 2025, with revenue of $113.56 million, and has missed earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.

The outlook remains challenging due to persistent losses and negative profit margins, though analyst consensus is unanimously bullish with 2 buy ratings. Key risks include execution challenges in AI infrastructure investments, reliance on financing for cash flow, and sensitivity to cryptocurrency market volatility impacting its strategic asset holdings.